Herb is a professor of immunology and has been an honorary consultant at the University of Nottingham and at the Queens Medical Centre &Nottingham University Hospitals NHS Trust (NUH) for 28 years (1990-2018). He was also Pro Vice Chancellor for Research at the university from 2002 to 2008 and a clinical director for pathology at NUH from 2002 to 2009. He is currently (2019-) Professor Emeritus in the Faculty of Medicine, University of Nottingham and Vice Chairman/Non-Executive Director of the NUH NHS Trust & Chairman of the NUH Quality Committee (2015-2019).
Founding fellow of the UK Academy of Medical Sciences (elected 1998).
Research Theme: As professor emeritus Herb continues with collaborative research
Current: Translational Cancer Research; in the Centre of Excellence on Autoimmunity in Cancer: Investigating early cancer detection and diagnosis of solid cancers inc Colorectal Cancer (MRC funded 2015-2019) -see selected publications
Herb plans to provide an Impact Case study on early cancer detection for REF 2021.
Other collaborative research: Human Allergy and in Host responses to Infections.
Nationally and internationally, he has served on many advisory and regulatory bodies covering health, science and business. He was a member of the governing body of the Medical Research Council (MRC)from 2004 to 2011. The MRC improves the health of people in the UK - and around the world - by supporting excellent science, and training the very best scientists.
Herb has been Chair and a member of numerous committees for UK medical royal colleges including the Royal College of Physicians and the Royal College of Pathologists.
Herb also has honorary degrees from the University of Birmingham and the University of the West Indies.
SULLIVAN, F. M., FARMER, E., MAIR, F.S., TREWEEK, S., KENDRICK, D., JACKSON, C., ROBERTSON, C., BRIGGS, A., MCCOWAN, C., BEDFORD, L., YOUNG, B., VEDHARA, K., GALLANT, S., LITTLEFORD, R., ROBERTSON, J., SEWELL, H., DORWARD, A., SARVESVARAN, J. and SCHEMBRI, S., 2017. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial BMC Cancer. 17(1), 187 MASSION PP, HEALEY GF, PEEK LJ, FREDERICKS L, SEWELL HF, MURRAY A and ROBERTSON JF, 2016. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
NEGM, OLA H., HAMED, MOHAMED R., SCHOEN, ROBERT E., WHELAN, RICHARD L., STEELE, ROBERT J., SCHOLEFIELD, JOHN, DILNOT, ELIZABETH M., KUMARA, H. M. C. SHANTHA, ROBERTSON, JOHN F. R. and SEWELL, HERBERT F., 2016. Human Blood Autoantibodies in the Detection of Colorectal Cancer PLOS ONE. 11(7),